Skip to main
STIM

Neuronetics Inc (STIM) Stock Forecast & Price Target

Neuronetics Inc (STIM) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neuronetics is a commercial-stage medical technology company that has performed well despite a decline in treatment session revenue, with positive customer feedback and plans for continued product roll-out. Their recent acquisitions and partnerships have positioned them as a leader in the evolving field of interventional psychiatry, with plans to launch a COMP360 psilocybin therapy and research agreement with Compass. Although there are potential risks, the company has a positive outlook with a Buy rating and $5 price target, backed by a strong customer base and expansion into new markets.

Bears say

Neuronetics is facing a number of challenges, including intense competition in the medical device industry, a shift in the market towards alternative treatment options, and pricing pressures. Additionally, their recent acquisition of Greenbrook TMS has yet to prove profitable and their entry into the psychedelic therapy market with COMP360 may face challenges and delays in obtaining regulatory approval. While the company has shown strong revenues and continued growth, increased operating expenses and potential disruptions in their business model may hinder their profitability in the long term.

Neuronetics Inc (STIM) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neuronetics Inc (STIM) Forecast

Analysts have given Neuronetics Inc (STIM) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Neuronetics Inc (STIM) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neuronetics Inc (STIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.